Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMuthalagu RamanathanGSGunjan L. ShahHSHyung C. Suh

Discussion

Loading...

Member takes

Overview

Open-label trial met primary endpoint of HPC mobilization, suggesting burixafor may enhance outcomes in multiple myeloma patients.

Key Points

  • All patients achieved ≥2x106 CD34+ cells/kg indicating successful mobilization for transplant.
  • 10 patients reported 277 adverse events, with 68% transplant-related and 15% attributed to study drugs.
  • This observational analysis used a Bayesian Optimal Phase 2 design to evaluate safety and efficacy.
  • Burixafor shows promise for improving HPC mobilization dynamics with favorable safety in multiple myeloma.

Cite This Study

Ramanathan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d759https://doi.org/10.1182/blood-2025-1050
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers2025
  2. 2Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy2025
  3. 3Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial2025
  4. 4Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease2025
  5. 5Enhanced CD34+ cell mobilizations, collections, and comparable safety profile with fixed-dose versus weight-based plerixafor dosing in patients with sickle cell disease receiving autologous CD34+ base-edited hematopoietic stem cells (BEAM-101) in the ongoing BEACON study2025 · 3 citations